Phosphodiesterase 7A-Deficient Mice Have Functional T Cells

Journal of Immunology

Volumn 171, Issue 12, 2003, Pages 6414-6420

  Yang, Guchen ^a   McIntyre, Kim W ^a   Townsend, Robert M ^a   Shen, Henry H ^a   Pitts, William J ^a   Dodd, John H ^a   Nadler, Steven G ^a   McKinnon, Murray ^a   Watson, Andrew J ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CD28 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; HEMOCYANIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; ISOENZYME; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE 7A; PHOSPHODIESTERASE 7A, HUMAN; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE-7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLOGY; EMBRYO; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENE DISRUPTION; GENE TARGETING; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; KNOCKOUT MOUSE; LYMPH NODE; LYMPHOCYTE ACTIVATION; MALE; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; NUTRITIONAL DEFICIENCY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLEEN; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

EID: 0346996880     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.12.6414     Document Type: Article

References (37)

1. Beavo, J. A. 1995. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:725.
2. Mehats, C., C. B. Andersen, M. Filopanti, S. L. Jin, and M. Conti. 2002. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol. Metab. 13:29.
3. Houslay, M. D. 1998. Adaptation in cyclic AMP signalling processes: a central role for cyclic AMP phosphodiesterases. Semin. Cell Dev. Biol. 9:161.
4. Essayan, D. M. 1999. Cyclic nucleotide phosphodiestase (PDE) inhibitors and immunomodulation. Biochem. Pharmacol. 57:965.
5. Kammer, G. M. 1988. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 9:222.
6. Torphy, T. J. 1998. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157:351.
7. Peachell, P. T., B. J. Undem, R. P. Scheimer, D. W. MacGlashan, Jr., L. M. Lichtenstein, L. B. Cieslinski, and T. J. Torphy. 1992. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol. 148:2503.
8. Compton, C. H., J. Gubb, R. Nieman, J. Edelson, O. Amit, A. Bakst, J. G. Ayres, J. P. Creemers, G. Schultze-Weminghaus, C. Brambilla, N. C. Barnes, for the International Study Group. 2001. Cilomilast, a selective phosphodiesterase 4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised dose-ranging study. Lancet 358:265.
9. Michaeli, T., T. J. Bloom, T. Martins, K. Loughney, K. Ferguson, M. Riggs, L. Rodgers, J. A. Beavo, and M. Wigler. 1993. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J. Biol. Chem. 268:12925.
10. Bloom, T. J., and J. A. Beavo. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA 93:14188.
11. Wang, P., P. Wu, R. W. Egan, and M. M., Billah. 2000. Cloning, characterization, and tissue distribution of mouse phosphodiesterase 7Al. Biochem. Biophys. Res. Comm. 276:1271.
12. Hetman, J. M., S. H. Soderling, N. A. Glavas, and J. A. Beavo. 2000. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc. Natl. Acad. Sci. USA 97:472.
13. Gardner, C., N. Robas, D. Cawkill, and M. Fidock. 2000. Cloning and characterization of the human and mouse PDE7B. a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Comm. 272:86.
14. Glavas, N. A., C. Ostenson, J. B. Schaefer, V. Vasta, and J. A. Beavo. 2001. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8Al and 7A3. Proc. Natl. Acad. Sci. USA 98:6319.
15. Han, P., X. Zhu, and T. Michaeli. 1997. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J. Biol. Chem. 272:16152.
16. Li, L., C. Yee, and J. A. Beavo. 1999. CD3-and CD28-dependent induction PDE7 required for T cell activation. Science 283:848.
17. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. 118:1945.
18. Ichimura, M., and H. Kase. 1993. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem. Biophys. Res. Comm. 193:985.
19. Zambrowlcz, B. P., G. A. Friedrich, E. C. Buxton, S. L. Lilleberg, C. Person, and A. T. Sands. 1998. Disruption and sequence identification of 2, 000 genes in mouse embryonic stem cells. Nature 392:608.
20. Christensen, S. B., A. Guider, C. J. Forster, J. G. Gleason, P. E. Bender, J. M. Karpinski, W. E. DeWolf, Jr., M. S. Barnette, D. C. Underwood, D. E. Griswood, et al., 1998. 1, 4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J. Med. Chem. 41:821.
21. Francis, S. H., J. L. Colbran, L. M. McAllister-Lucas, and J. D. Corbin. 1994. Zinc interaction and conserved motif of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J. Biol. Chem. 269:22477
22. Xu, R. X., A. M. Hassell, D. Vanderwall, M. H. Lambert, W. D. Holmes, M. A. Luther, W. J. Rocque, M. V. Milbum, Y. Zhao, H. Ke, and R. T. Nolte. 2000. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science 288:1822.
23. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
24. Barnette, M. S., S. B. Christensen, D. A. Essayan, M. Grous, U. Prabhakar, J. A. Rush, A. Kagey-Sobotka and T. J. Torphy. 1998. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. 284:420.
25. Hatzelmann, A., and C. Schudt. 2001. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297:267.
26. Kanka, N., and S. Watanabe. 2001. Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Biochem. Pharmacol. 62:495.
27. Stein, C. A. 2001. The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. Invest. 108:641.
28. Manning, C. D., M. Burman, S. B. Christensen, L. B. Cieslinski, D. M. Essayan, M. Grous, T. J. Torphy, and M. S. Barnette. 1999. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. J. Pharmacol. 128:1393.
29. Essayan, D. M., S.-K. Huang, B. J. Undem, A. Kagey-Sobotka, and L. M. Litchtenstein. 1994. Modulation of antigen-and mitogen-induced proliferative responses of peripheral blood mononuclear cells by non-selective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Immunol. 153:3408.
30. Martinez, A., A. Castro, C. Gil, M. Miralpeix, V. Segarra, T. Domenech, J. Beleta, J. M. Casacuberta, F. Azorin, B. Pina, and P. Puigdomenech. 2000. Benzyl derivatives of 2, 1, 3-benzo-and benzothieno[3, 2-α]thiadiazine 2, 2-dioxides: first phosphodiesterase 7 inhibitors. J. Med. Chem. 43:683.
31. Bames, M. J., N. Cooper, R. J. Davenport, H. J. Dyke, F. P. Galleway, F. C. A. Galvin, L. Gowers, A. F. Haughan, C. Lowe, J. W. G. Meissner, et al. 2001. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg. Med. Chem. Lett. 2001:1081.
32. Dodge, K. L., S. Khouangsathiene, M. S. Kapiloff, R. Mouton, E. V. Hill, M. D. Houslay, L. K. Langeberg, and J. D. Scott. 2001. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J. 20:1921.
33. MacKenzie, S. J., G. S. Baillie, I. McPhee, G. B. Bolger, and M. D. Houslay. 2000. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. J. Biol. Chem. 275:16609.
34. Perry, S. J., G. S. Baillie, T. A. Kohout, I. McPhee, M. M. Magiera, K. L. Ang, W. E. Miller, A. J. McLean, M. Conti, M. D. Houslay, and R. J. Lefkowitz. 2002. Targeting of cyclic AMP degradation to β2-adrenergic receptors by β-arrestins. Science 298:834.
35. + effector T cells by stimulation in the presence of cyclic adenosine 5'-monophosphate-elevating agents. J. Immunol. 169:1159.
36. Suresh, R., M. Vig, S. Bhatia, E. P. Goodspeed, B. John, U. Kandpal, S. Srivastava, A. George, R. Sen, V. Bal, et al. 2002. Pentoxifylline functions as an adjuvant in vivo to enhance T cell immune responses by inhibiting activation-induced death. J. Immunol. 169:4262.
37. Lee, R., S. Wolda, E. Moon, J. Esselstyn, C. Hertel, and A. Lerner. 2002. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell. Signal. 14:277.